ABT · NYSE · ·
下次财报:2026年10月21日
US$100.960.0%9月29日 收盘
Abbott makes and sells medicines, diagnostic tests, nutrition products, and medical devices.
各项收入占比是对quarter ended 2026-03-31的估算,并非来自已提交报告的数字。
Established Pharmaceutical Products
Branded generic medicines sold outside the United States, including treatments for digestive conditions, women's health, heart and metabolic conditions, pain, and respiratory infections.
Diagnostic systems and tests
Laboratory instruments, test kits, and rapid tests used to help detect or monitor conditions such as infections, cancer, heart problems, and thyroid disorders.
Nutrition products
Infant formula, adult nutrition drinks and powders, and products used for feeding patients in healthcare institutions, including Similac, Ensure, and PediaSure.
Heart and other medical devices
Products include pacemakers, heart valves, devices used to treat narrowed blood vessels, and implanted devices for chronic pain or movement disorders.
FreeStyle Libre
A continuous glucose monitoring system with a sensor worn on the body to measure glucose levels for people with diabetes.
Cologuard
A stool-based test used to screen for colorectal cancer; Abbott discussed it on its earnings call as part of its cancer diagnostics business.
三项评分,每一项都是相对我们在Medical Devices覆盖的 143 家公司 的百分位。刻意分开而不揉成一个总分:便宜、上涨和经营得好是三件不同的事,一个数字会把它们是哪一件藏起来。
处于同行业中游
最近一个月被刻意剔除:回报往往在 7 到 12 个月内延续,而最新的一个月往往反转。这描述的是股价已经走过的路,不说明它接下来会怎么走。
处于同行业中游
这些是收益率,所以数值越高越便宜——亏损的公司会排在最后,而不是被剔除。便宜不等于好:高收益率往往意味着股价是有原因才跌下来的。 五项指标齐全。
六项全部可判定
管理层怎么使用这笔钱——只按财报能回答的部分计分,绝不按占总数的比例计分。
这是对该公司在同行中所处位置的描述,不是投资建议。 评分更新于 2026年9月30日。
Abbott develops, makes, and sells healthcare products around the world. Its businesses include branded generic medicines sold outside the United States, diagnostic tests and equipment, nutrition products, and devices for heart conditions, diabetes, and other needs. Its buyers include healthcare providers, distributors, retailers, government agencies, and consumers.
基于 Abbott Laboratories 自己向 SEC 提交的申报文件。数字如实呈报,每股历史已重述到今天的股数口径。 这是对一门生意的描述——不是投资建议,也不是买卖任何证券的推荐。
生意在变大吗,它是否创造真实的现金?
显示 Abbott Laboratories 评级历史 40 个季度中的 2 个。 其余 38 个可回溯到 2016年9月。